Literature DB >> 7516706

Solution structure of residues 1-28 of the amyloid beta-peptide.

J Talafous1, K J Marcinowski, G Klopman, M G Zagorski.   

Abstract

The three-dimensional solution structure of residues 1-28 of the amyloid beta-peptide was determined using nuclear magnetic resonance spectroscopy, distance geometry, and molecular dynamic techniques. The nuclear magnetic resonance data used to derive the structure consisted of nuclear Overhauser enhancements, vicinal coupling constants, and temperature coefficients of the amide-NH chemical shifts. The beta-peptide is the major proteinaceous component of amyloid deposits in Alzheimer's disease. In membrane-like media, the peptide folds to form a predominately alpha-helical structure with a bend centered at residue 12. The side chains of histidine-13 and lysine-16 are close, residing on the same face of the helix. Their proximity may constitute a binding motif with the heparan sulfate proteoglycans. The molecular details of the structure shown here could facilitate the design of rational treatments to curtail the binding of heparan sulfate proteoglycans or to prevent an alpha-helix-->beta-sheet conversion that may occur during the early stages of amyloid formation in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516706     DOI: 10.1021/bi00191a006

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption.

Authors:  C M Yip; J McLaurin
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

2.  A study of the α-helical intermediate preceding the aggregation of the amino-terminal fragment of the β amyloid peptide (Aβ(1-28)).

Authors:  Ana V Rojas; Adam Liwo; Harold A Scheraga
Journal:  J Phys Chem B       Date:  2011-10-18       Impact factor: 2.991

3.  Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.

Authors:  Eric Martineau; Janna M de Guzman; Lioudmila Rodionova; Xianqi Kong; Paul M Mayer; Ahmed M Aman
Journal:  J Am Soc Mass Spectrom       Date:  2010-05-31       Impact factor: 3.109

4.  Parity-violation energy of biomolecules-IV: protein secondary structure.

Authors:  Francesco Faglioni; Inmaculada García Cuesta
Journal:  Orig Life Evol Biosph       Date:  2010-12-16       Impact factor: 1.950

5.  Alzheimer's disease: halothane induces Abeta peptide to oligomeric form--solution NMR studies.

Authors:  Pravat K Mandal; Jay W Pettegrew; Dennish W McKeag; Ratna Mandal
Journal:  Neurochem Res       Date:  2006-06-29       Impact factor: 3.996

Review 6.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

7.  The interaction of beta-amyloid protein fragment (12-28) with lipid environments.

Authors:  T G Fletcher; D A Keire
Journal:  Protein Sci       Date:  1997-03       Impact factor: 6.725

8.  Probing the origins of increased activity of the E22Q "Dutch" mutant Alzheimer's beta-amyloid peptide.

Authors:  F Massi; J E Straub
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

Review 9.  The toxicity in vitro of beta-amyloid protein.

Authors:  L L Iversen; R J Mortishire-Smith; S J Pollack; M S Shearman
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

10.  Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Abeta peptide [Abeta(25-35)].

Authors:  O M El-Agnaf; G B Irvine; G Fitzpatrick; W K Glass; D J Guthrie
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.